Histone deacetylase inhibitors: A potential epigenetic treatment for Duchenne muscular dystrophy

Silvia Consalvi, Valentina Saccone, Chiara Mozzetta

Research output: Contribution to journalArticle

Abstract

Duchenne muscular dystrophy (DMD) is a life-threatening genetic disease that currently has no available cure. A number of pharmacological strategies that aim to target events downstream of the genetic defect are currently under clinical investigation, and some of these are outlined in this report. In particular, we focus on the ability of histone deacetylase inhibitors to promote muscle regeneration and prevent the fibro-adipogenic degeneration of dystrophic mice. We describe the rationale behind the translation of histone deacetylase inhibitors into a clinical approach, which inspired the first clinical trial with an epigenetic drug as a potential therapeutic option for DMD patients.

Original languageEnglish
Pages (from-to)547-560
Number of pages14
JournalEpigenomics
Volume6
Issue number5
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Histone Deacetylase Inhibitors
Duchenne Muscular Dystrophy
Epigenomics
Inborn Genetic Diseases
Regeneration
Clinical Trials
Pharmacology
Muscles
Therapeutics
Pharmaceutical Preparations

Keywords

  • chromatin
  • epigenetics
  • HDAC inhibitors
  • muscle stem cells
  • muscular dystrophy
  • regeneration

ASJC Scopus subject areas

  • Genetics
  • Cancer Research
  • Medicine(all)

Cite this

Histone deacetylase inhibitors : A potential epigenetic treatment for Duchenne muscular dystrophy. / Consalvi, Silvia; Saccone, Valentina; Mozzetta, Chiara.

In: Epigenomics, Vol. 6, No. 5, 01.10.2014, p. 547-560.

Research output: Contribution to journalArticle

@article{1a93cdf748ff4b32b171564f6792eeed,
title = "Histone deacetylase inhibitors: A potential epigenetic treatment for Duchenne muscular dystrophy",
abstract = "Duchenne muscular dystrophy (DMD) is a life-threatening genetic disease that currently has no available cure. A number of pharmacological strategies that aim to target events downstream of the genetic defect are currently under clinical investigation, and some of these are outlined in this report. In particular, we focus on the ability of histone deacetylase inhibitors to promote muscle regeneration and prevent the fibro-adipogenic degeneration of dystrophic mice. We describe the rationale behind the translation of histone deacetylase inhibitors into a clinical approach, which inspired the first clinical trial with an epigenetic drug as a potential therapeutic option for DMD patients.",
keywords = "chromatin, epigenetics, HDAC inhibitors, muscle stem cells, muscular dystrophy, regeneration",
author = "Silvia Consalvi and Valentina Saccone and Chiara Mozzetta",
year = "2014",
month = "10",
day = "1",
doi = "10.2217/epi.14.36",
language = "English",
volume = "6",
pages = "547--560",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Histone deacetylase inhibitors

T2 - A potential epigenetic treatment for Duchenne muscular dystrophy

AU - Consalvi, Silvia

AU - Saccone, Valentina

AU - Mozzetta, Chiara

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Duchenne muscular dystrophy (DMD) is a life-threatening genetic disease that currently has no available cure. A number of pharmacological strategies that aim to target events downstream of the genetic defect are currently under clinical investigation, and some of these are outlined in this report. In particular, we focus on the ability of histone deacetylase inhibitors to promote muscle regeneration and prevent the fibro-adipogenic degeneration of dystrophic mice. We describe the rationale behind the translation of histone deacetylase inhibitors into a clinical approach, which inspired the first clinical trial with an epigenetic drug as a potential therapeutic option for DMD patients.

AB - Duchenne muscular dystrophy (DMD) is a life-threatening genetic disease that currently has no available cure. A number of pharmacological strategies that aim to target events downstream of the genetic defect are currently under clinical investigation, and some of these are outlined in this report. In particular, we focus on the ability of histone deacetylase inhibitors to promote muscle regeneration and prevent the fibro-adipogenic degeneration of dystrophic mice. We describe the rationale behind the translation of histone deacetylase inhibitors into a clinical approach, which inspired the first clinical trial with an epigenetic drug as a potential therapeutic option for DMD patients.

KW - chromatin

KW - epigenetics

KW - HDAC inhibitors

KW - muscle stem cells

KW - muscular dystrophy

KW - regeneration

UR - http://www.scopus.com/inward/record.url?scp=84913616554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913616554&partnerID=8YFLogxK

U2 - 10.2217/epi.14.36

DO - 10.2217/epi.14.36

M3 - Article

C2 - 25431946

AN - SCOPUS:84913616554

VL - 6

SP - 547

EP - 560

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 5

ER -